{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LDQHNR51/3a5fd031-b53b-4061-b2ce-e51ff5f69c21/PDF","dcterms:extent":"173 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LDQHNR51/34a4869d-436e-474d-9608-e0e1f068bca1/TEXT","dcterms:extent":"26 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-LDQHNR51","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2019","dc:creator":"Rožman, Samo","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:70"},{"@xml:lang":"sl","#text":"str. 139-144"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:3246715","URN:URN:NBN:SI:doc-LDQHNR51"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"anaemia"},{"@xml:lang":"sl","#text":"anemija"},{"@xml:lang":"en","#text":"cancer"},{"@xml:lang":"en","#text":"erythropoiesis-stimulating agents"},{"@xml:lang":"en","#text":"iron"},{"@xml:lang":"sl","#text":"rak"},{"@xml:lang":"sl","#text":"rekonbinantni eritropoetin"},{"@xml:lang":"sl","#text":"železo"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Obravnava anemij in pomanjkanja železa v onkologiji| Management of anaemia and iron deficiency in patients with cancer|"},"dc:description":{"@xml:lang":"sl","#text":"Anemija in pomanjkanje železa sta pogosta zapleta v onkologiji, zlasti pri bolnikih na zdravljenju s kemoterapijo. Vzroki za anemijo so številni, posledice pa so slabša kvaliteta življenja in krajše celokupno preživetje. Zdravljenje pri bolnikih s solidnimi raki in hematološkimi malignomi poteka z rekombinantnimi eritropoetini, pripravki z železom, transfuzijami eritrocitov, ali kombinacijami naštetih metod. Posebno podskupino predstavljajo bolniki z mielodisplastičnimi sindromi, kjer zdravljenje anemije poteka z rekombinantnimi eritropoetini in kroničnimi transfuzijami eritrocitov. Zaradi številnih transfuzij lahko takšni bolniki razvijejo preobremenitev z železom, ki prizadene številne organe. V primeru preobremenitve z železom in sočasne anemije je terapija izbora uporaba kelatorjev železa"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-LDQHNR51","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-LDQHNR51"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-LDQHNR51/3a5fd031-b53b-4061-b2ce-e51ff5f69c21/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-LDQHNR51/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-LDQHNR51"}}}}